27
>
Kinetex 2.6 µm Advantage On Your UHPLC System
Increased peak capacity is achieved with
Kinetex 2.6 µm
when compared to sub-2 µm
columns at the same pressure. Take full advantage of your UHPLC system with Kinetex
2.6 µm columns.
14
5
4
6
8
7
9
10
11
12
2
1
13
3
15
1.4e6
19861
1.3e6
1.2e6
1.1e6
1.0e6
9.0e5
8.0e5
7.0e5
6.0e5
5.0e5
4.0e5
3.0e5
2.0e5
1.0e5
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
Intensity
, cps
1.6
1.8
2.0
2.2
min
14
5
4
6
8
7
910
11
12
2
1
13
3
15
1.4e6
19862
1.3e6
1.2e6
1.1e6
1.0e6
9.0e5
8.0e5
7.0e5
6.0e5
5.0e5
4.0e5
3.0e5
2.0e5
1.0e5
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
Intensity
, cps
1.6
1.8
2.0
2.2
min
App ID 19861
App ID 19862
Data generated by Quotient Bioresearch, U.K.
** ACQUITY and UPLC are registered trademarks of Waters Corporation. API 5000 is a trademark of AB SCIEX.
Phenomenex is not affiliated with Waters Corporation.
*Comparative separations may not be representative of all applications.
Traditional 1.7 µm C18
Peak Capacity: 34.4 @ 7700 psi (531 bar)*
Kinetex 2.6
µm C18
Peak Capacity: 43.5 @ 7700 psi (531 bar)*
26 % Increase in Peak
Capacity*
Conditions for both columns:
Dimensions: 50 x 2.1 mm
Mobile Phase: A: 0.1 % Formic acid in Acetonitrile
B: 0.1 % Formic acid (aq)
Gradient: Time (min)
0.00
0.25
1.80
1.90
1.91
2.50
% B
95
95
10
10
95
95
Temperature: 40 ºC
Detection: MS
Instrument: **Waters ACQUITY
®
Binary UPLC
®
**API 5000
TM
QQQ
Flow Rate: Kinetex: 1.4 mL/min
Traditional: 0.8 mL/min
Sample: 1. Haloperidol
2. Diltiazem
3. Terfenadine
4. Cimetidine
5. Acetaminophen
6. Sulfathiazole
7. Pindolol
8. Quinidine
9. Acebutolol
10. Chlorpheniramine
11. Tripolidine
12. Prednisolone
13. Nortriptyline
14. 2-hydroxy-5-methyl benzaldehyde
15. Hexanophenone
It Doesn't Stop Here!
34 % increase in peak capacity and a 3.5 x's increase
in sensitivity was achieved! Download technical note
TN-1104 at www.phenomenex.com/kinetex
(technical resource/technical library) to learn how.
Phenomenex
l
WEB: www.phenomenex.com